Mivebresib

Overview

Mivebresib (ABBV-075) is a potent and orally active bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a K i of 1.5 nM.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Blood Disease | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Acute Myeloid Leukemia | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Epigenetic Reader Domain | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-100015
• CAS No.: 1445993-26-9
• Molecular Formula: C22H19F2N3O4S
• Molecular Weight: 459.47
• Purity: 99.29%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.44 mM); Clear solution
• Availability: In-stock

Source

Original product source